Key result
Combined tofacitinib and ruxolitinib treats refractory T-cell prolymphocytic leukemia with a JAK3 mutation.
Why the study?
Refractory T-cell prolymphocytic leukemia with a JAK3 mutation lacks established effective treatments, motivating exploration of combined JAK inhibition.
Case report describing the combined use of tofacitinib and ruxolitinib for refractory T-PLL with a JAK3 mutation.
Answers are grounded in this paper and cite their sources.
May support dual JAK inhibition in JAK3-mutated refractory T-PLL; leaves open efficacy and safety in prospective studies.
A 62-year-old male presented with lymphocytosis and splenomegaly. A diagnosis of T-PLL was made based on bone marrow examination. The patient was initially observed but after a year developed progr...
No takes yet. Share an insight, caveat, or question.
Gomez-Arteaga et al. (2019) studied this question. Combined use of tofacitinib and ruxolitinib was utilized for the treatment of refractory T-cell prolymphocytic leukemia with a JAK3 mutation in a 62-year-old male.
Synapse has enriched 10 related papers. Consider them for comparative context: